Clover Corporation Limited · ASX:CLV

Clover — FY2014 Earnings Presentation

13 slides from Clover's earnings presentation, Sep 24, 2014

  1. Slide 1: FY 2014 Results

    For personal use only FY 2014 Results Res lts 24 September 2014

  2. Slide 2: Vision and Mission Statement

    For personal use only VISION AND MISSION STATEMENT • Vision: To optimise the health and development of infants and children. Mission: To deliver science based bioactives to the global infant, children and medical food markets that provide health benefits. 2

  3. Slide 3: FY2014 Results

    FY2014 RESULTS For personal use only AUD million 4E Reported 4E Reported 4E Reported 4E Normalised* 31 July 2014 31 July 2013 31 July 2012 31 July 2012 Revenue $27 2 $27.2 $44 1 $44.1 $38 4 $38.4 $38 4 $38.4 Profit before tax $1.2 $8.5 $6.4 $7.4 EBITDA $1.6 $8.8 $6.7 $7.9 EBIT $1.1 $8.3 $6.2 $7.4 Ta

  4. Slide 4: Balance Sheet

    BALANCE SHEET For personal use only 31 July 2014 AUD million Reported Reported Movement 31 July 2014 31 July 2013 0.3È Cash $8 0 $8.0 $8 3 $8.3 5.1È Trade Receivables $6.9 $12.0 5Ç Inventories $16.5 $14.0 2.5 1.8È Total Current Assets $32.9 $34.7 0.4È PPE/Intangible Assets $4.9 $5.3 2.0È Total Asset

  5. Slide 5: Cash Flow

    CASH FLOW For personal use only Year ended 31 July 2014 AUD million Reported From Operations 31 July 2014 EBITDA $1.6 Working Capital Movement $3.5 Net Interest $0 1 $0.1 Tax Paid ($2.0) Cash Flow from Operations $3.2 Financing Activities ($3.3) Capex ($0.2) N tC Net Cash h Fl Flow ($0 3) ($0.3) 5

  6. Slide 6: FY2014 Key Items

    For personal use only FY2014 KEY ITEMS • Significant negative revenue impact NZ WPC (-38.3% PCP) • Some recovery evident CY14 Q3 • Oceania and Asia remain key geographic sales regions • Derivative powder products gaining traction • Continued gross margin pressure, down to 29.0% (PCP 35.1%) • Fixed c

  7. Slide 7: Delivery Systems Based on a Variety of Nutritional Bioactives

    DELIVERY SYSTEMS BASED ON A VARIETY OF NUTRITIONAL BIOACTIVES For personal use only • Product portfolio includes encapsulated Sales Revenue based on powders containing marine oil, algal oils, Diversified Bioactives in FY2014 other specialty oils and important micronutrients • Encapsulation technolog

  8. Slide 8: Sales by Geography/Product

    SALES BY GEOGRAPHY/PRODUCT For personal use only FY2014 Geographic • Continued strong presence though Oceania and Asia Australia/New Zealand 22% Asia 58% • Encapsulation technology strong and proven Europe 14% Americas 6% FY2014 Products Oil 4% Encapsulated Powders 96% 8

  9. Slide 9: Research & Development Expenditure

    RESEARCH & DEVELOPMENT EXPENDITURE For personal use only Targeted expenditure aimed at developing high margin new product opportunities whilst continuing to develop million ($) the strong existing customer relationships 2.5 # 2.0 * 1.5 15 1.0 0.5 0.0 FY09 FY10 FY11 FY12 FY13 FY14 FY15 R&D Expenditur

  10. Slide 10: Growth Objectives

    For personal use only GROWTH OBJECTIVES • Continued focus on the infant formula market – Specialist delivery systems – Developing new markets/applications – Improved bioactive protection • Develop medical food program – Product pipeline to improve the health of preterm infants – Major clinical trial

  11. Slide 11: FY2015 Outlook & Priorities

    For personal use only FY2015 OUTLOOK & PRIORITIES • Work with existing customers to regain lost revenue • Continued organic growth with emphasis on Oceania, Oceania Asia and Europe • Investment in NZ spray dryer to partner with customers to supply new sources of oil to address new market opportuniti

  12. Slide 12: Thank You

    For personal use only THANK YOU Questions? 12

  13. Slide 13: Disclaimer

    For personal use only DISCLAIMER The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s

Clover — FY2014 Earnings Presentation on 6ix